145 related articles for article (PubMed ID: 35289081)
1. Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.
Jin Z; He Q; Zhu X; Zhu M; Wang Y; Wu XA; Lv Q; Xiang X
Basic Clin Pharmacol Toxicol; 2022 May; 130(5):592-605. PubMed ID: 35289081
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM
Br J Clin Pharmacol; 2019 Mar; 85(3):530-539. PubMed ID: 30428505
[TBL] [Abstract][Full Text] [Related]
5. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
Rytkönen J; Ranta VP; Kokki M; Kokki H; Hautajärvi H; Rinne V; Heikkinen AT
Biopharm Drug Dispos; 2020 Feb; 41(1-2):72-88. PubMed ID: 31925778
[TBL] [Abstract][Full Text] [Related]
9. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
11. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
[TBL] [Abstract][Full Text] [Related]
12. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
[TBL] [Abstract][Full Text] [Related]
17. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
18. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
[TBL] [Abstract][Full Text] [Related]
19. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
20. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]